![]() |
|
|
Division of Biopharmaceutics (P.C.N., R.M.S., A.J.V., M.K.B., T.J.C.V.B.) and Pharmaceutical Technology (M.E.M.J.M.), Leiden-Amsterdam Center for Drug Research, University of Leiden, Leiden, The Netherlands
| |
Summary |
|---|
|
|
|---|
Progressive hypocholesterolemia is a feature associated with a number
of cancers of different origin, and it is caused by the high expression
of low-density lipoprotein (LDL) receptors (LDLrs) on many tumor cell
types. Selective delivery of chemotherapeutics using LDL as a carrier
has therefore been proposed, but the endogenous nature of LDL hampers
its pharmaceutical application. In the current study, we explored the
possibility of synthesizing liposomes that mimic LDL from commercially
available lipids and proteins. Small unilamellar liposomes were created
(28.9 ± 0.9 nm) and complexed with 5.8 ± 0.7 molecules of
human recombinant apolipoprotein E (apoE). On intravenous injection
into rats, the liposomes retained their aqueous core, structural
integrity, and the majority of the preassociated apoE.
[3H]Cholesteryl oleate-labeled apoE-enriched liposomes
showed a relatively long serum half-life (>5 hr), and a low uptake by
cells of the reticuloendothelial system was observed (<0.8% of the
injected dose at 30 min after injection). Pretreatment of rats with
17
-ethinyl estradiol, which induces the expression of the LDLr on
the liver and adrenals, led to a 2.5-fold accelerated serum clearance
(t1/2 = 123 ± 10 min) and a
selectively increased uptake of liposomes by the liver (2.0-fold) and
adrenals (3.8-fold). The liver association of the liposomes was coupled
to the lysosomal uptake route, similarly as for LDL. In
vitro studies using B16 melanoma cells showed that the liposomes
bound exclusively to the LDLr via their apoE moiety (90,000 liposomes/cell), with a 14-fold higher affinity
(Kd = 0.77 ± 0.09 nM) than LDL itself. Because of their favorable
properties, we anticipate that these apoE-enriched liposomes are
advantageous compared with native LDL in the development of a selective
LDLr-targeted antitumor therapy.
| |
Introduction |
|---|
|
|
|---|
Many studies have reported the J- or U-shaped relation between plasma total cholesterol levels and all-cause mortality (1). High cholesterol levels are correlated to mortality from cardiovascular diseases, but epidemiological studies have indicated that tumor-associated hypocholesterolemia is a feature associated with a number of cancers of different origin, as was recently reviewed (2). This inverse relation between plasma cholesterol levels and cancer has been found mainly in hematological malignancies such as acute myelogenous leukemia but also for adrenal adenoma and cancers of the colon, lung, breast, and prostate (2, 3).
The mechanism underlying hypocholesterolemia is postulated to be the overuse of cholesterol by cancer cells because they are characterized by accelerated growth and division (termed reverse causality), as reviewed by Markel and Brook (2). This mechanism has been underscored by the finding that a declining plasma cholesterol level, but not a stable low level, is related to subsequent mortality from cancers of the hemopoietic system, esophagus, and prostate (4, 5). Moreover, trials have correlated the normalization of the low pretreatment cholesterol levels with successful chemotherapy or curative surgery and remission of the disease (6).
Within the blood compartment, cholesterol is mainly transported by LDL, spherical lipid particles that are recognized and taken up via their exposed apoB-100 moiety by the LDLr (7). The LDLr is expressed on a variety of tissues, such as the liver and adrenals. Indirect evidence for the overuse of cholesterol by cancer cells is derived from the overexpression of the LDLr in acute myelogenous leukemia (3-100-fold), colon cancer (6-fold), adrenal adenoma (8-fold), lung carcinoma, brain tumors, and metastatic prostate tumors, as reviewed by Firestone (3).
Based on the excessive need of cancer cells for cholesterol, it has been suggested that tumor cell growth can be impeded by limiting the rate of utilization of cholesterol or inhibiting its synthesis (8). On the other hand, the selective uptake of LDL by tumor cells raised the possibility of targeting chemotherapeutics by using LDL as a drug carrier (3). The principle to use native LDL for drug targeting purposes has been demonstrated in vitro (3, 9) and in vivo (10, 11). The necessity to isolate LDL from human serum, however, hampers its pharmaceutical application.
As models for LDL, both 20-30-nm microemulsions (12) and 100-200-nm liposomes (13) have been synthesized. Although LDL and microemulsions consist of a hydrophobic core that is emulsified by a phospholipid monolayer, (unilamellar) liposomes contain an aqueous core that is surrounded by a phospholipid bilayer. Delipidated detergent-solubilized apoB-100 was subsequently complexed as ligand for the LDLr (13-15). These reconstituted LDL-like particles were shown to display affinity for the LDLr in vitro (13, 15), but in vivo results on these complexes have not been reported. LDL was recently shown to have an optimal size of 23-24 nm for maximum LDLr affinity (16), which is related to the conformation of apoB-100 as determined by circular dichroism (16). Concomitant with the potential loss of the structural integrity of such a large 514-kDa protein during delipidation and solubilization, it can be expected that the particle size of the reconstituted LDL is crucial for obtaining LDL-typical in vivo behavior when using solubilized apoB-100 as a ligand for the LDLr.
The 34-kDa glycoprotein apoE, a constituent of triglyceride-rich lipoproteins such as chylomicrons and VLDL, is also a high affinity ligand for the LDLr, although it is structurally unrelated to apoB-100. The LDLr-binding domain of apoE is a 20-amino acid region comprising residues 140-160 (17). Although apoE that is devoid of lipid lacks LDLr-binding activity (18), apoE-containing HDL binds with a very high affinity (20-25-fold higher than LDL) to the LDLr with a Kd value of ~0.12 nM (18, 19). As many as four apoE molecules assembled on a phospholipid surface can bind a single LDLr, and when more than one of the apoE molecules binds, the apparent affinity is increased 25-50-fold (18).
Recently, we observed that the apoE-mediated metabolic behavior of triglyceride-rich emulsions was dependent on the particle size. Large emulsions (>100 nm) were taken up by a liver-specific non-LDLr recognition site, but the in vivo clearance of small emulsions (<50 nm) by the liver and adrenals was completely mediated by the LDLr (20). In the current study, we investigated the feasibility of synthesizing small liposomes that on association with commercially available human recombinant apolipoprotein show affinity for the LDLr in vivo. The potential application of these carriers for tumor-directed drug targeting was assessed in vitro using LDLr-expressing B16 murine melanoma cells.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Recombinant human apoE was a generous gift from
Tikva Vogel (Bio-Technology General, Rehovot, Israel) and was supplied
as a lyophilized powder containing 76% apoE, 11.7%
L-cysteine, and 12.0% NaHCO3 (21).
ApoE was dissolved in PBS, pH 7.4 (2.0 mg/ml), and stored under argon
at
80°. Carrier-free 125I in NaOH,
[3H]CO, [3H]inulin, and
[14C]DOPC were purchased from Amersham
(Buckinghamshire, UK). Triolein (99% pure) and EYPC (98%) were from
Fluka (Buchs, Switzerland). L-
-Lysophosphatidylcholine
(99%), cholesterol (>99%), BSA (fraction V), 17
-EE, and
phospholipase A2 (isolated from Crotalus
atrox venom) were obtained from Sigma Chemical (St. Louis,
MO). CO (97%) was from Janssen (Beersse, Belgium). Cholesterol
oxidase, cholesterol esterase, peroxidase type II (200 units/mg),
Precipath L, EDTA, and a solution containing 50,000 IU of penicillin
and 50 mg/ml streptomycin were from Boehringer-Mannheim Biochemica
(Mannheim, Germany). HEPES, 5-carboxyfluorescein, and
L-glutamine were from Merck (Darmstadt, Germany), and
Triton X-100 was from BDH Chemicals (Poole, UK). Dulbecco's modified
Eagle medium was from GIBCO BRL (Gaithersburg, MD). Fetal calf serum
was obtained from Hyclone Laboratories (Logan, UT), and a solution of
2.5% (w/v) trypsin in Hanks' balanced salt solution without
Ca2+ and Mg2+ was purchased
from Flow Laboratories (Irvine, UK). All other chemicals were of
analytical grade.
Preparation and purification of liposomes. Liposomes were prepared by sonication according to a modification of the procedure used by Ginsburg et al. (12) with 50 mg of total lipid at a EYPC/CO molar ratio of 25:1. The lipids were hydrated in 11.4 ml of 0.1 M KCl and 0.01 M Tris·HCl, pH 8.0, and sonicated for 1 hr using a Soniprep 150 (MSE Scientific Instruments, Crawley, UK) at 18 µM output that is equipped with a water bath for temperature (54°) maintenance. When indicated, liposomes were synthesized in the presence of a self-quenching concentration (100 mM) of 5-carboxyfluorescein, 10-150 µCi of [3H]CO, 2-3 µCi of [14C]DOPC, or 50-100 µCi of [3H]inulin. Liposomes were purified and concentrated by density gradient ultracentrifugation according to the method of Redgrave et al. (22) using NaCl/KBr/EDTA density solutions, pH 8.0, in a Beckman SW 40 Ti rotor at 40,000 rpm for 18-22 hr at 4°. Liposomes, which are visible as a narrow opalescent layer at approximately three fourths of the tube height, were routinely isolated by aspiration. Alternatively, the gradients were fractionated (0.6-ml fractions) at a flow rate of 1.2 ml/min using an LKB (Uppsala, Sweden) Bromma 2132 Microperpex peristaltic pump, starting at the bottom of the tube. The fractions were assayed for density using a DMA 40 digital density meter from Mettler (Graz, Austria). Liposomes were stored at 20° under argon and used for characterization and metabolic studies within 5 days after preparation, during which no physicochemical changes occurred, as determined on the basis of particle size analysis by photon correlation spectroscopy, agarose gel electrophoresis, and/or [3H]inulin retention (described below).
Characterization of liposomes. The EYPC and CO contents of the purified liposomes and ultracentrifugation fractions were determined using the Boehringer-Mannheim enzymatic kits for phosphatidylcholine and cholesterol, respectively. Precipath L was used as an internal standard. Radioactivity was routinely counted after the addition of Emulsifier Safe (Packard, Meriden, CT). Particle size and homogeneity of the liposomes were assayed by freeze fracture electron microscopy (as described below) or photon correlation spectroscopy using a Malvern 4700 C system (Malvern Instruments, Malvern, UK). Measurements were performed at 27° and a 90-degree angle between laser and detector. The net negative charge was determined by subjecting the liposomes to 0.75% (w/v) agarose gel electrophoresis, pH 8.8, with 0.075 M Tris·HCl, 0.080 M hippuric acid, and 0.65 mM EDTA buffer. RF values were determined relative to the front marker bromphenol blue.
Freeze fracture electron microscopy.
Aliquots of liposome
suspensions were positioned between copper platelets (Balzers,
Fürstentum, Liechtenstein) and cryofixed by rapid freezing
(105 K/sec) in liquid propane with the use of a
KF80 plunge freezing device (Reichert-Jung, Vienna, Austria). The
frozen samples were fractured in a Balzers BAF400D freeze etching
device at
150° and 2 × 10
7 mm Hg. The
fracture planes were replicated by shadowing with platinum/carbon (2.5 nm) at an angle of 45°, followed by evaporation of carbon at 90°
(30 nm) to strengthen the replica and ensure conductance. After
thawing, the replicas were cleaned overnight using 30% sodium
hypochlorite, washed with demineralized water, and examined on 400-mesh
grids (Balzers) using a Philips (Eindhoven, The Netherlands) EM 201 transmission electron microscope at an acceleration voltage of 80 kV.
Isolation of LDL. Human LDL was isolated from the blood of healthy fasted volunteers by differential ultracentrifugation (1.019 < d < 1.063 g/ml) as previously described (22). Subsequently, LDL was dialyzed against PBS containing 1 mM EDTA, pH 7.4, with repeated changes of buffer and sterilized by filtration through a 0.22-µm filter (Millipore, Molsheim, France). The protein concentration was determined according to the method of Lowry et al. (23) using BSA as a standard.
Radiolabeling of apoE. ApoE was radioiodinated at pH 10.0 with carrier-free 125I according to the ICl method (24) as previously described (25). Free 125I was removed by Sephadex G-25 gel filtration and extensive dialysis against PBS containing 1 mM EDTA, pH 7.4, with repeated changes of buffer. More than 98% of the radiolabel was trichloroacetic acid precipitable. The specific activity of 125I-apoE was 420-475 dpm/ng.
Association of apoE with liposomes. Liposomes were incubated with 125I-apoE at various ratios for 30 min at 37°, and the incubation mixtures were subjected to density gradient ultracentrifugation according to the method of Redgrave et al. (22) with subsequent fractionation as detailed above. For in vivo experiments, liposomes were incubated with 125I-apoE at an EYPC/apoE ratio of 10:0.1 (w/w), allowing complete liposomal incorporation of 125I-apoE.
Effect of apoE on the liposomal integrity. To determine the liposomal character and effect of apoE on particle integrity, an enzymatic method was adopted that was based on the selective digestion of phosphatidylcholine within the outer layer of phospholipid-stabilized particles (26). [14C]DOPC-labeled liposomes (5 mg of phospholipid) were incubated at room temperature, with or without preincubation (30 min at 37°) with 300 µg of apoE, in 0.1 M Tris·HCl, 0.5% (w/v) BSA, and 7 mM CaCl2, pH 7.4, at a total volume of 20 ml. Phospholipase A2 (10 units) was added at t = 0. When indicated, Triton X-100 was added after 30 min of incubation at a final concentration of 1% (v/v). At the indicated times, 800-µl samples were withdrawn, and reaction was terminated by lipid extraction according to the method of Bligh and Dyer (27). [14C]DOCP (RF = 0.25), [14C]oleoyl phosphatidylcholine (RF = 0.06), and [14C]oleate (RF = 0.97) were separated by thin layer chromatography [CHCl3/CH3OH/H2O/acetic acid 70:30:4:2 (v/v/v/v)]. Lipids were visualized with iodine vapor, scraped off, and counted in 10 ml of Emulsifier Safe. [14C]DOPC-labeled emulsions of 49 ± 11 nm were prepared as previously described (20, 28) and used as a reference for particles that are emulgated by a phospholipid monolayer.
Effect of apoE and/or serum on the liposomal density and surface charge. Liposomes (0.5 mg of phospholipid) that were labeled with [3H]CO, [14C]DOPC, or [3H]inulin were incubated (30 min at 37°) with 1 ml of rat serum, without and with prior incubation (30 min at 37°) with apoE [phospholipid/apoE 10:1 (w/w)]. Subsequently, liposomes were reisolated by density gradient ultracentrifugation according to the method of Redgrave et al. (22), and gradients were fractionated and assayed as described above. Proteins (10-20 µg) within the fractions were occasionally separated on 5-20% sodium dodecyl sulfate-polyacrylamide gels. The relative amounts of apolipoproteins were calculated by densitometric scanning of Coomassie blue R-250-stained gels using a GS300 Scanning Densitometer from Hoefer Scientific Instruments (San Francisco, CA). Alternatively, aliquots of incubation mixtures were subjected to agarose gel electrophoresis as detailed above, resulting gels were fractionated, and radioactivity was counted on dissolution (overnight at 37°) in 10 ml of Emulsifier Safe.
Serum decay, liver uptake, and tissue distribution of liposomes
and apoE in rats.
Male Wistar rats (mass, 230-280 g) that were
fed ad libitum with regular chow were anesthetized by
intraperitoneal injection of sodium pentobarbital (15 mg/kg body
weight), and the abdomens were opened. 125I-apoE
(2.5 µg) or liposomes that were labeled with
[3H]CO, [3H]inulin, or
125I-apoE (1.0-2.5 mg of phospholipid) were
injected via the inferior vena cava. At the indicated times, blood
samples and tissue lobules were taken and processed as previously
described in detail (28). At 30 or 120 min after injection, the rats
were killed, and their organs were excised and weighed. Radioactivity
in [3H]inulin-containing serum, liver, and
other tissue samples was counted after combustion (recovery, >97%) in
a Packard Tri-Carb 306 Sample Oxidizer and corrected for the serum
radioactivity in the tissues at the time of sampling (28). The
125I-containing serum and tissue samples were
counted in a Packard gamma counter. When indicated, serum obtained at
30 min after injection was subjected to density gradient
ultracentrifugation according to the method of Redgrave et
al. (22), and gradients were fractionated and assayed as
described. In some studies, rats were pretreated with 17
-EE
dissolved in propylene glycol at 5 mg/kg body weight or similar amounts
of propylene glycol alone for 3 successive days (29).
Intrahepatic processing of liposomal CO in rats. To determine the rate of CO hydrolysis within the liver, [3H]CO-labeled liposomes (1.0 mg of phospholipid) were injected into anesthetized rats as described. At the indicated times, liver lobules were taken and immediately frozen in liquid N2. On homogenization in ice-cold PBS, pH 7.4, lipids were extracted according to the method of Bligh and Dyer (27) and separated using thin layer chromatography [heptane/diethyl ether/acetic acid 60:40:1 (v/v/v)]. Cholesterol (RF = 0.23) and CO (RF = 0.85) were visualized with iodine vapor, scraped off, and counted in 15 ml of Hionic Fluor (Packard). Occasionally, the biliary secretion of 3H radioactivity was determined by insertion of a catheter in the bile duct. Bile samples were counted for radioactivity after bleaching by the addition of 10 µl of 30% (v/v) H2O2. Also, aliquots of bile were extracted at pH 7.0 according to the method of Bligh and Dyer (27) to distinguish between bile acid- and cholesterol (ester)-associated 3H-radioactivity.
Subcellular distribution of liposomes. [3H]CO-labeled liposomes (1.0 mg of phospholipid) were injected into anesthetized rats as described. At 120 min after injection, the liver was perfused with 50 ml of ice-cold 0.25 M sucrose and 10 mM Tris·HCl buffer, pH 7.4, and divided into subcellular fractions by differential centrifugation exactly according to the method of De Duve et al. (30). The fractions were assayed for radioactivity, protein, and the activity of several marker enzymes (acid phosphatase, glucose-6-phosphatase, and lactate dehydrogenase) as previously described (30).
Culture of B16 melanoma cells. B16 (wild-type) murine melanoma cells (provided by Dr. A. Begg, The Netherlands Cancer Institute, Amsterdam, The Netherlands) were cultured at 37° in a humidified 5% CO2/95% air atmosphere in 500-cm2 flasks (Costar, Cambridge, MA) containing 20 ml of Dulbecco's modified Eagle's medium supplemented with 10% (v/v) heat-inactivated fetal calf serum, 2 mM L-glutamine, 50 IU/ml penicillin, and 50 µg/ml streptomycin. Cells were subcultured twice a week by detachment using 0.25% trypsin in Ca2+- and Mg2+-deficient Hanks' buffer, followed by renewal of medium the next day. The cellular protein content was determined according to the method of Lowry et al. (23) using BSA as a standard.
Binding and association of apoE-enriched liposomes to B16 melanoma cells in culture. At 2-3 days before the experiment, cells were transferred to 22-mm multiwell culture dishes at a density of 20,000-40,000 cells/well. When subconfluency was achieved, the culture medium was replaced by preincubation medium [including 1% (w/v) BSA instead of fetal calf serum]. The cells were washed three times (10, 10, and 30 min) and then cultured for 18 hr in this medium. After two washes with preincubation medium, experiments were started by the addition of the indicated amounts of LDL and/or liposomes in this medium. When liposomes were preincubated (30 min at 37°) with apoE [EYPC/apoE 10:0.5 (w/w)], unbound protein was removed by ultracentrifugation as detailed above. To determine the specific binding of the apoE-enriched liposomes, the cells were incubated (3 hr at 4°) with the [3H]CO-labeled particles. Subsequently, the cells were washed five times with ice-cold wash buffer (0.15 M NaCl, 2.5 mM CaCl2, 50 mM Tris·HCl, pH 7.4) containing 0.2% (w/v) BSA, followed by two washes with the same buffer without BSA. The cells were lysed by the addition of 1 ml of 0.1 N NaOH, and the amounts of protein as well as radioactivity in the lysate were determined. The association of apoE-enriched liposomes to the cells was assayed by incubating the cells (3 hr at 37°) with the [3H]CO-labeled particles and the indicated additives. The culture plates were then placed on ice, and the cell-associated radioactivity was determined as described.
| |
Results |
|---|
|
|
|---|
Synthesis and characterization of liposomes.
Particles were
created by sonication of EYPC and ([3H])CO at a
molar ratio of 25:1, followed by concentration and purification using
density gradient ultracentrifugation. A typical distribution pattern of
the lipids over the gradient is depicted in Fig.
1 (top). The majority of
constituents coincided within an opalescent layer (fractions 14 and 15)
recovered at a mean density of 1.014 g/ml, which is intermediate
between the range of densities of LDL (1.019-1.063 g/ml) and VLDL
(0.96-1.006 g/ml). The high molar ratio of phospholipid (EYPC) versus
that of neutral lipid (CO) (28.9 ± 2.5; mean ± standard
error, five experiments) indicates a liposomal character of these
particles, which was confirmed by the possibility of incorporating a
self-quenching concentration of 5-carboxyfluorescein during particle
synthesis that was retained during purification by ultracentrifugation
(not shown). In addition, some emulsion particles were formed
(fractions 19 and 20), as indicated by their low density (
1.006
g/ml), a low EYPC/CO ratio of 7.6 ± 1.6 (mean ± variation,
two experiments), and their inability to incorporate
carboxyfluorescein. The purified liposomes were homogeneous particle
populations (low polydispersity of 0.198 ± 0.001) with a mean
size of only 28.9 ± 0.9 nm (mean ± standard deviation, 21 experiments) as measured by photon correlation spectroscopy, predicting
a unilamellar particle structure. For comparison, under similar
conditions, the size of human LDL was determined to be 20.8 ± 0.7 nm with a polydispersity of 0.192 ± 0.005 (mean ± standard deviation, three experiments). The average liposome size and
polydispersity did not change during storage at room temperature for
4 months after preparation, indicating their long term stability.
Freeze fracture electron microscopy revealed that the apparent
diameters of the vast majority of particles were in the range of 15-30
nm, which confirms their small size and homogeneity (Fig. 1,
bottom). The electrophoretic mobility of the liposomes
relative to bromphenol blue was low (0.12 ± 0.01; mean ± standard deviation, seven experiments) and lower than that of LDL
(0.21 ± 0.01; mean ± standard deviation, three
experiments), confirming their low negative surface charge. The
combination of a small size and low surface charge is beneficial with
respect to avoiding phagocytotic uptake by cells of the RES (31) and
scavenger receptors on endothelial
cells,1 respectively.
|
Association of apoE with liposomes. To mimic LDL and display a high affinity for the LDLr, at least four copies of apoE should become associated with the liposomes (18), without disruption of the liposome bilayer structure. Incubation of 125I-apoE with increasing amounts of liposomes resulted in an increased recovery of apoE with the particles, as apparent from a (partial) shift in the density of apoE (>1.15 g/ml) toward the liposomal density (Fig. 2). As a consequence, the density of the liposomes increased dependent on the apoE concentration to 1.04-1.05 g/ml (fraction 11), which is in the density range of LDL (1.019-1.063 g/ml). The absence of an additional density shift at a further reduction of the liposomal phospholipid amount from 1.0 to 0.13 mg indicates that saturation of the liposomal shell with apoE is achieved at an EYPC/apoE weight ratio of 10:0.25. From the established correlation between the amount of phospholipid and particle number (32), it can be calculated that 5.8 ± 0.7 molecules of apoE (mean ± standard deviation, three experiments) are acquired per liposome particle at this ratio. Acquisition of apoE did not substantially change the electrophoretic mobility of the liposomes on agarose.
|
Effect of apoE association on the liposomal structure. The effect of apoE insertion into the liposomal bilayer was determined by phospholipid digestion using phospholipase A2, to which only those phospholipid molecules are accessible that are exposed in the outer layer (26). Radioactive DOPC was used as a marker of the liposomal phospholipid because oleate groups constitute 27% of the fatty acids in EYPC (32). Incubation of liposomes with phospholipase A2 led to the hydrolysis of [14C]DOPC reaching a plateau value of ~60-65%, which increased to 100% only after the addition of Triton X-100 (Fig. 3). DOPC within the inner layer apparently is not accessible to the enzyme unless the liposomal structure is disrupted. As a control, DOPC within a similarly sized emulsion, which is stabilized by a phospholipid monolayer, was quantitatively digested without the need of particle disruption. Preincubation of liposomes with sufficient apoE to saturate the particle [EYPC:apoE 10:0.6 (w/w)] did not substantially change the biphasic appearance of the DOPC digestion curve (Fig. 3), indicating that the liposomal unilamellar structure is retained on insertion of apoE.
|
Effect of serum on the integrity of apoE-enriched liposomes. Liposomes that are designed for intravenous administration should retain their structural integrity and preassociated apoE within the circulation; therefore, the effect of apoE and/or rat serum on the lipid constituents of liposomes was checked. The addition of shell-saturating amounts of apoE [EYPC:apoE 10:1 (w/w)] resulted in an increased particle density as judged from the shifted patterns of [3H]CO and [14C]DOPC over the gradients after ultracentrifugation (Fig. 4). These observations are consistent with the patterns obtained with 125I-apoE (Fig. 2). Incubation of the liposomes with serum (with or without preincubation with apoE) led to an even higher increase in the density of the nonexchangable liposomal [3H]CO constituent (1.05-1.06 g/ml). Under these conditions, [14C]DOPC appeared as two bands. The band spanning fractions 7-10 coincided with HDL as determined by the cholesteryl ester distribution over the gradient obtained from rat serum (not shown), indicating a partial transfer of radiolabel from liposomes to HDL.
|
Serum decay, liver uptake, and extrahepatic distribution of the
apoE-enriched liposomes in rats.
The serum decay and liver uptake
in rats of [3H]CO-labeled liposomes in the
absence or presence of apoE are depicted in Fig. 5. The liposomes showed a very low uptake
by the liver (2.9 ± 2.4% of the injected dose) and a high
remaining fraction within the serum (81.3 ± 2.5%) at 30 min
after injection. The serum clearance and liver uptake (6.8 ± 3.4%) did not significantly change (p > 0.05)
after preincubation with apoE (Fig. 5, left). At 30 min after injection, the combined recovery of radiolabel in the lungs and
spleen was negligible (<0.8%; not shown), indicating a low affinity
of the apoE-enriched liposomes for cells of the RES. Normal rats show
virtually no expression of a functional LDLr (33); the affinity for
this receptor was therefore assessed in 17
-EE-treated rats. This
treatment leads to a selective up-regulation of the LDLr on rat liver
parenchymal cells and an increased uptake of LDL by the adrenal glands
(29, 34). Placebo treatment of rats with propylene glycol did not
affect the serum half-life of apoE-enriched liposomes, and the
association with the liver at 30 min after injection (10.9 ± 1.3%) was not significantly changed (p > 0.05) (Fig. 5, right). In contrast, the serum clearance was
substantially (2.5-fold) increased on pretreatment with 17
-EE (t1/2 = 123 ± 10 min versus
>5 hr). Concomitantly, a selective 2.0- and 3.8-fold increased
specific uptake (i.e., per gram wet weight) was observed for the liver
(3.7 ± 0.8% versus 1.9 ± 0.3%) and adrenals (8.4 ± 0.7% versus 2.2 ± 0.2%), respectively, at 120 min after
injection (Fig. 6, right),
which is indicative of an LDLr-dependent metabolic behavior.
|
|
Effect of apoE and in vivo circulation on the integrity of the liposomal core. To investigate the suitability of these liposomes for the targeting of hydrophilic agents, the integrity of the liposomal core was assessed in vivo using water-soluble [3H]inulin as core marker. Sonication of liposomes in a buffer containing [3H]inulin with subsequent purification by ultracentrifugation and extensive dialysis resulted in the recovery of 0.24 ± 0.02% (mean ± standard deviation, three experiments) of the added inulin within the liposomes. These data imply an internal volume of 0.55 ± 0.04 µl/mg of phospholipid, provided the incorporated inulin did not leak from the liposomes during isolation. Because this value was predicted for 30-nm particles on the nomogram relating lipid weight, diameter, and internal volume for unilamellar vesicles (32), inulin leakage apparently did not occur. Incubation of these liposomes in PBS for 0 or 60 min at 37° also did not lead to substantial leakage of entrapped inulin (5.4%) (Fig. 7, left). In contrast, incubation of liposomes with excess apoE [EYPC:apoE 10:1 (w/w)] resulted in the instantaneous partial loss of [3H]inulin (50.3%), which was independent of the incubation period (0-60 min). This indicates a temporary liposomal destabilization during insertion of apoE and suggests that associated apoE does not dissociate or exchange between liposomes, which would lead to a gradually increasing loss of inulin with incubation time.
|
Intrahepatic processing of apoE-enriched liposomes in rats.
Cellular uptake as mediated by the LDLr should be coupled to a
lysosomal uptake route, which was checked by performing a subcellular distribution of the liposomal marker [3H]CO
within the liver at 30 min after injection of apoE-enriched liposomes
into a 17
-EE-pretreated rat. The distribution pattern of
[3H]CO was intermediate between those of the
lysosomal marker acid phosphatase and the microsomal marker
glucose-6-phosphatase, whereas the distribution of the cytoplasmic
marker lactate dehydrogenase was clearly different (Fig.
8). Because endosomes are recovered within the microsomal fraction (35), these data indicate that the liver
association of the apoE-enriched liposomes is coupled to an endosomal
uptake route toward lysosomes.
|
-EE-pretreated rats.
Although the liver association rate of the liposomes was higher within
17
-EE-pretreated rats (Fig. 5), the rate of
[3H]CO hydrolysis was similar under both
conditions, with 50% release of
[3H]cholesterol between 30 and 60 min after
injection (Fig. 9).
|
Binding and association of apoE-enriched liposomes to B16 melanoma cells. To verify the affinity and apoE-mediated specificity of liposomes for the LDLr in vitro, their binding and uptake characteristics were determined on B16 melanoma cells. Recently, we reported that these tumor cells show a high expression of the LDLr (~220,000/cell) with a high affinity for LDL (11 nM) and specific uptake of LDL in vivo when C57/Bl6 mice were subcutaneously inoculated (36). On the basis of the binding curves of [3H]CO-labeled apoE-enriched liposomes in the absence or presence of excess unlabeled particles, it is evident that the liposomes show a high affinity for a binding site on B16 cells with a calculated dissociation constant (Kd) of 0.77 ± 0.09 nM and a maximal binding (Bmax) value of 1298 ± 20 ng of liposomal phospholipids/mg of cell protein (Fig. 10). With the assumed values of 1.09 × 106 cells/mg of cell protein and 7.62 × 1013 liposomes/mg of phospholipid, it can be calculated that ~90,000 liposomes/cell can be maximally bound.
|
|
| |
Discussion |
|---|
|
|
|---|
The severe adverse side effects of many cytostatics, which are a consequence of their nonspecific body distribution, can preclude the administration of these drugs at a dosage that establishes maximum efficacy. Current strategies that aim at optimization of drug delivery to cancer cells involve vehicles that selectively target to tumor cells, such as monoclonal antibodies, growth factors, and hormones. A general problem associated with these compounds, however, is their poor cellular internalization. The increased LDLr expression on certain tumors, as related to the overuse of cholesterol to meet their high rate of membrane synthesis, has stimulated research on LDL as a drug carrier. LDL is effectively bound, internalized, and processed by the LDLr, but the need for isolation from human blood precludes its large-scale pharmaceutical application. To overcome this problem, we explored the feasibility of synthesizing particles from commercially available lipids and recombinant protein, with physicochemical and biological properties similar to those of native LDL.
A sonication procedure was applied to synthesize homogeneous small
unilamellar liposomes from EYPC and CO, with a size (~29 nm) and an
overall negative charge (RF
= 0.12) similar to those of LDL, that can be stored for
4
months at room temperature. Because of its amphipathic character, apoE
spontaneously associates with the liposomes, leading to an increase in
liposomal density from 1.014 to 1.04-1.05 g/ml, which is similar to
LDL. Insertion of apoE led to a transient liposome destabilization, as
evident from partial inulin leakage from the aqueous core, but did not disrupt the liposomal structure. Approximately five or six molecules of
apoE associated per particle, predicting a maximum affinity for the
LDLr (18).
Liposomes that are designed for intravenous injection should retain their integrity within the circulation. Incubation of apoE-enriched liposomes with serum did not have an major effect on the apoE or CO moiety. Serum opsonins, which could promote opsonophagocytosis of liposomes by cells of the RES (31), also were not detected on Coomassie blue-stained polyacrylamide gels. In serum, only a partial transfer occurred of liposomal phospholipid to HDL, which presumably indicates mutual phospholipid exchange as mediated via phospholipid transfer factors (37). Despite this phospholipid transfer, the integrity of the liposomal aqueous core was retained in vivo in that no leakage of inulin was observed when administered intravenously into rats. These data are in accordance with the observation that a much smaller compound, like carboxyfluorescein, is retained within phosphatidylcholine liposomes even in the presence of a purified phospholipid transfer factor (37). The preservation of the liposomal aqueous core in vivo also indicates that in contrast to versatile triglyceride-rich emulsions (28), endogenous apoE is not efficiently acquired from serum because apoE insertion would lead to leakage (and thus a decreased half-life) of entrapped inulin.
The liposomes showed a relatively long half-life in rats of >5 hr,
comparable to LDL, as a consequence of its low affinity for the RES
(Kupffer cells, lungs, and spleen). Previous association of apoE did
not alter their serum kinetics, which was expected because rats show
virtually no expression of a functional LDLr (33). Selective
up-regulation of the LDLr on rat liver parenchymal cells by
pretreatment with 17
-EE (29, 34) indeed resulted in a 2.5-fold
shortened serum half-life and an increased uptake by the liver
(2.0-fold) and adrenals (3.8-fold) but only when liposomes had been
previously enriched with apoE. The liver uptake rate of these
apoE/liposome complexes was comparable to that reported for
[3H]CO-labeled LDL (~40% at 60 min after
injection) (38). These data indicate that a substantial amount of apoE
is retained on the liposome after injection, which was confirmed by a
5-fold reduction of the liver uptake of free
125I-apoE (62.4 ± 5.2%) after incubation
with liposomes (12.5 ± 1.5%).
On LDLr-mediated association of the apoE-enriched liposomes with the
liver of 17
-EE-pretreated rats, the liposomes were subsequently internalized via an endocytotic uptake route and degraded, as is
evident from the time-dependent hydrolysis of CO. This phenomenon also
occurred in control rats, which can be attributed to the low expression
of the LDLr but may also result from an LDLr-independent uptake route
of an as-yet-unknown nature. Preliminary data showed that in both
17
-EE and control rats, the released cholesterol was eventually
secreted into the bile as bile acids after a lag time of ~20 min (not
shown).
Because these liposomes are designed for tumor-directed drug delivery, their uptake characteristics were determined on LDLr-expressing B16 melanoma cells in vitro. Indeed, an apoE-specific binding as mediated by the LDLr was observed with an affinity (Kd = 0.77 ± 0.09 nM) that was 14.3-fold higher than that for LDL (Kd = 11 nM) (35). The number of apoE-enriched liposomes that was maximally bound per cell (Bmax) was ~2.5-fold lower (~90,000) than that for LDL (~220,000) (36). This apparent discrepancy can be explained by the multireceptor binding model of Pitas et al. (20), who observed that up to four times as many LDL than apoE-containing HDLc particles were required for LDLr saturation at maximal binding to human fibroblasts. The fact that we determined a 2.5-fold (instead of a 4-fold)-reduced maximal particle binding can result from the strong dependency of the LDLr expression on the cellular confluency. Because the LDLr expression decreases with increasing confluency,2 slight variations in the confluency will affect the calculation of Bmax.
With respect to tumor targeting, the presented apoE-enriched liposomes
possess various advantageous properties compared with LDL. First, the
affinity of the LDLr for apoE is much higher than that for apoB-100 as
established using human fibroblasts (20-25-fold) (19) and now
demonstrated for B16 melanoma cells (14-fold). This might constitute an
important observation with respect to future drug targeting application
in that LDL shows a relatively high nonspecific (non-LDLr-mediated)
uptake in vivo. Although 60-80% of the clearance is
mediated by the LDLr, as described by Brown and Goldstein (7), the
remainder is cleared via non-LDLr-mediated pathways (39).
Down-regulation of the LDLr on nontumor tissues, as in the clinical
application of cytotoxic LDL, will result in an even higher
contribution of non-LDLr-mediated LDL clearance. The much higher
affinity of apoE-enriched liposomes for the LDLr might thus lead to
more specific drug targeting. Second, the use of commercially available
lipids and, in particular, the availability of human recombinant apoE
(in contrast to apoB-100) facilitates the application of these
recombinant particles as pharmaceutical drug carriers. Third, the
presence of an aqueous particle core allows the incorporation of
hydrophilic compounds. This property could be particularly interesting
with respect to the in vivo tumor delivery of antisense
oligodeoxynucleotides. Because of their instability in serum and
nonspecific body distribution, these compounds have been coupled to
hydrophobic structures, such as cholesterol, and subsequently complexed
with LDL (40). Although the cellular uptake and efficacy of these
oligodeoxynucleotides were improved in vitro, they seemed to
rapidly dissociate from LDL in vivo (40), presumably because
of their bulky anionic character. Because a flip-flop mechanism did not
occur for liposomal phospholipid (i.e., exchange of phospholipid
between the inner and outer layers) and is certainly not expected for
polyanionic oligodeoxynucleotides, leakage of derivatized
oligodeoxynucleotides would be prevented on liposomal incorporation.
Fourth, the liposomes showed a low tendency to aggregate because their
size was stable for
4 months at room temperature, and they could
therefore be used for in vivo application for extended
periods without the need of particle size preservation, which is in
contrast to LDL or emulsions (15, 28). Finally, the higher affinity for
the LDLr of the apoE-enriched liposomes compared with LDL allows a more
efficient tumor localization of the liposomes compared with LDL/drug
complexes by virtue of a more efficient competition with endogenous LDL
for LDLr-mediated tumor uptake.
In conclusion, we demonstrated the feasibility of using an endogenous receptor-mediated uptake route for liposome delivery. We anticipate that these apoE-enriched liposomes represent a conceptual advance in the development of a selective LDLr-targeted antitumor therapy compared with LDL.
| |
Acknowledgments |
|---|
We thank Tikva Vogel for generously supplying human recombinant apoE.
| |
Footnotes |
|---|
Received December 2, 1996; Accepted May 27, 1997
1 P. C. N. Rensen and T. J. C. van Berkel, unpublished observations.
2 Versluis, A.J., M.K. Bysterbosch, and T.J.C. van Berkel, unpublished observations.
Send reprint requests to: Dr. Patrick C. N. Rensen, Division of Biopharmaceutics, Leiden-Amsterdam Center for Drug Research, University of Leiden, Sylvius Laboratories, P.O. Box 9503, 2300 RA Leiden, The Netherlands. E-mail: p.rensen{at}lacdr.leidenuniv.nl
| |
Abbreviations |
|---|
LDL, low-density lipoprotein; apo, apolipoprotein; BSA, bovine serum albumin; CO, cholesteryl oleate; DOPC, dioleoyl phosphatidylcholine; EE, ethinyl estradiol; EYPC, egg yolk phosphatidylcholine; HDL, high-density lipoprotein; LDLr, low-density lipoprotein receptor; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; PBS, phosphate-buffered saline; RES, reticuloendothelial system; VLDL, very low-density lipoprotein.
| |
References |
|---|
|
|
|---|
| 1. | Rose, G. and M. J. Shipley. Plasma lipids and mortality: a source of error. Lancet 1:523-526 (1980)[Medline]. |
| 2. | Markel, A. and G. J. Brook. Cancer and hypocholesterolemia. Isr. J. Med. Sci. 30:787-793 (1994)[Medline]. |
| 3. | Firestone, R. A. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjugate Chem. 5:105-113 (1994)[Medline]. |
| 4. |
Pekkanen, J.,
A. Nissinen,
E. Vartiainen,
J. T. Salonen,
S. Punsar, and
M. J. Karvonen.
Changes in serum cholesterol level and mortality: a 30-year follow-up: the Finnish Cohorts of the Seven Countries Study.
Am. J. Epidemiol.
139:155-165 (1994) |
| 5. |
Iribarren, C.,
D. M. Reed,
R. Chen,
K. Yano, and
J. H. Dwyer.
Low serum cholesterol and mortality: which is the cause and which is the effect?
Circulation
92:2396-2403 (1995) |
| 6. | Niendorf, A., H. Nägele, D. Gerding, U. Meyer-Pannwitt, and A. Gebhardt. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int. J. Cancer 61:461-464 (1995)[Medline]. |
| 7. |
Brown, M. S. and
J. L. Goldstein.
A receptor-mediated pathway for cholesterol homeostasis.
Science (Washington D. C.)
232:34-47 (1986) |
| 8. |
Goldstein, J. L.,
A. S. Helgeson, and
M. S. and Brown.
Inhibition of cholesterol synthesis with compactin renders growth of human cultured cells dependent on the low density lipoprotein receptor.
J. Biol. Chem.
254:5403-5409 (1979) |
| 9. | De Smidt, P. C. and Th. J. C. Van Berkel. LDL-mediated drug targeting. Crit. Rev. Ther. Drug Carrier Syst. 77:99-120 (1990). |
| 10. |
Masquelier, M.,
S. Vitols, and
C. Peterson.
Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Cancer Res.
46:3842-3847 (1986) |
| 11. |
Vitols, S.,
B. Angelin,
S. Ericsson,
G. Gahrton,
G. Juliusson,
M. Masquelier,
C. Paul,
C. Peterson,
M. Rudling,
K. Söderberg-Reid, and
U. Tidefelt.
Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.
Proc. Natl. Acad. Sci. USA
87:2598-2602 (1990) |
| 12. |
Ginsburg, G. S.,
D. M. Small, and
D. Atkinson.
Microemulsions of phospholipids and cholesteryl esters: protein-free models of low density lipoprotein.
J. Biol. Chem.
257:8216-8227 (1982) |
| 13. | Lundberg, B., K. Hong, and D. Papahadjopoulos. Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim. Biophys. Acta 1149:305-312 (1993)[Medline]. |
| 14. |
Ginsburg, G. S.,
M. T. Walsh,
D. M. Small, and
D. Atkinson.
Reassembled plasma low density lipoproteins: phospholipid-cholesterol ester-apoprotein B complexes.
J. Biol. Chem.
259:6667-6673 (1984) |
| 15. | Lundberg, B. and L. Suominen. Preparation of biologically active analogs of serum low density lipoprotein. J. Lipid Res. 25:550-558 (1984)[Abstract]. |
| 16. |
Galeano, N. F.,
R. Milne,
Y. L. Marcel,
M. T. Walsh,
E. Levy,
T. D. Ngu'yen,
A. Gleeson,
Y. Arad,
L. Witte,
M. Al-Haideri,
S. C. Rumsey, and
R. J. Deckelbaum.
Apoprotein structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small but not in triglyceride-rich LDL of normal size.
J. Biol. Chem.
269:511-519 (1994) |
| 17. |
Wilson, C. M. R.
Wardell, K. H. Weisgraber, R. W. Mahley, and D. A. Agard. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.
Science (Washington D. C.)
252:1817-1822 (1991) |
| 18. |
Innerarity, T. L.,
R. E. Pitas, and
R. W. Mahley.
Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts.
J. Biol. Chem.
254:4186-4190 (1979) |
| 19. |
Pitas, R. E.,
T. L. Innerarity,
K. S. Arnold, and
R. W. Mahley.
Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc.
Proc. Natl. Acad. Sci. USA
76:2311-2315 (1979) |
| 20. | Rensen, P. C. N., N. Herijgers, M. H. Netscher, S. C. J. Meskers, M. van Eck, and Th. J. C. van Berkel. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38:1070-1084 (1997)[Abstract]. |
| 21. |
Vogel, T.,
K. H. Weisgraber,
M. I. Zeevi,
H. B. Ben-Artzi,
A. Z. Levanon,
S. C. Rall, Jr.,
T. L. Innerarity,
D. Y. Hui,
J. M. Taylor,
D. Kanner,
Z. Yavin,
B. Amit,
H. Aviv,
M. Gorecki, and
R. W. Mahley.
Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E.
Proc. Natl. Acad. Sci. USA
82:8696-8700 (1985) |
| 22. | Redgrave, T. G., D. C. K. Roberts, and C. E. West. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal. Biochem. 65:42-49 (1975)[Medline]. |
| 23. |
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr, and
R. J. Randall.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:265-275 (1951) |
| 24. | McFarlane, A. S. Efficient trace-labelling of proteins with iodine. Nature (Lond.) 182:53-58 (1958)[Medline]. |
| 25. |
Rensen, P. C. N. and
Th. J. C. Van Berkel.
Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich emulsions in vitro and in vivo.
J. Biol. Chem.
271:14791-14799 (1996) |
| 26. |
Tajima, S.,
S. Yokoyama, and
A. Yamamoto.
Effect of lipid particle size on association of apolipoproteins with lipid.
J. Biol. Chem.
258:10073-10082 (1983) |
| 27. | Bligh, E. G. and W. J. Dyer. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:911-917 (1959). |
| 28. | Rensen, P. C. N., M. C. M. Van Dijk, E. C. Havenaar, M. K. Bijsterbosch, J. K. Kruijt, and Th. J. C. Van Berkel. Selective targeting of antivirals by recombinant chylomicrons: a new therapeutic approach to hepatitis B. Nat. Med. 1:221-225 (1995)[Medline]. |
| 29. |
Chao, Y. S.,
E. E. Windler,
G. C. Chen, and
R. J. Havel.
Hepatic catabolism of rat and human lipoproteins in rats treated with 17 -ethinyl estradiol.
J. Biol. Chem.
254:11360-11366 (1979) |
| 30. | De Duve, C., B. C. Pressman, R. Gianetto, R. Wattiaux, and F. Appelmans. Tissue fractionation studies: 6. Intracellular distribution patterns of enzymes in rat liver tissue. Biochem. J. 60:604-617 (1955)[Medline]. |
| 31. | Patel, H. M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:39-90 (1992)[Medline]. |
| 32. | New, R. R. C. Liposomes: A Practical Approach. IRL Press, Oxford (1990). |
| 33. | Nagelkerke, J. F., H. F. Bakkeren, K. Kuipers, R. J. Vonk, and Th. J. C. Van Berkel. Hepatic processing of the cholesteryl esters from low density lipoprotein in the rat. J. Biol. Chem. 261:8909-8913 (1986). |
| 34. |
Bertolotti, M. and
D. K. Spady.
Effect of hypocholesterolemic doses of 17 -ethinyl estradiol on cholesterol balance in liver and extrahepatic tissues.
J. Lipid Res.
37:1812-1822 (1996)[Abstract].
|
| 35. |
Van Berkel, Th. J. C.,
J. K. Kruijt, and
H. M. Kempen.
Specific targeting of high density lipoproteins to liver hepatocytes by incorporation of a tris-galactoside-terminated cholesterol derivative.
J. Biol. Chem.
260:12203-12207 (1985) |
| 36. | Versluis, A. J., P. J. Van Geel, H. Oppelaar, T. J. C. Van Berkel, and M. K. Bijsterbosch. Receptor-mediated uptake of low-density lipoprotein by B16 melanoma cells in vitro and in vivo in mice. Br. J. Cancer 74:525-532 (1996)[Medline]. |
| 37. | Damen, J., J. Regts, and G. Scherphof. Transfer of [14C]phosphatidylcholine between liposomes and human plasma high density lipoprotein: partial purification of a transfer-stimulating plasma factor using a rapid transfer assay. Biochim. Biophys. Acta 712:444-452 (1 |